UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $29.25 Million Stock Holdings in Chemed Corporation $CHE

Key Points

• UBS Asset Management has reduced its stake in Chemed Corporation by 1.4%, holding 47,528 shares valued at $29.25 million following a sale of 669 shares.
• While hedge funds have varied positions on Chemed, with some increasing their stakes significantly, approximately 95.85% of the stock is held by institutional investors.
• Chemed has seen recent analyst rating changes, including an upgrade by Jefferies Financial Group to a "buy" with a price target increase from $490 to $550.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC reduced its position in shares of Chemed Corporation (NYSE:CHE - Free Report) by 1.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 47,528 shares of the company's stock after selling 669 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 0.32% of Chemed worth $29,245,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Kayne Anderson Rudnick Investment Management LLC increased its position in shares of Chemed by 2.6% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 597,175 shares of the company's stock worth $367,454,000 after purchasing an additional 15,041 shares during the period. Neuberger Berman Group LLC grew its position in Chemed by 3.9% during the 1st quarter. Neuberger Berman Group LLC now owns 521,212 shares of the company's stock worth $320,712,000 after acquiring an additional 19,650 shares during the last quarter. Boston Trust Walden Corp grew its position in shares of Chemed by 1.7% in the 1st quarter. Boston Trust Walden Corp now owns 246,351 shares of the company's stock worth $151,585,000 after buying an additional 4,179 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Chemed by 9.7% during the first quarter. Dimensional Fund Advisors LP now owns 218,675 shares of the company's stock valued at $134,547,000 after buying an additional 19,421 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Chemed by 3.4% in the first quarter. Northern Trust Corp now owns 215,523 shares of the company's stock worth $132,616,000 after purchasing an additional 6,988 shares during the last quarter. Institutional investors and hedge funds own 95.85% of the company's stock.

Chemed Stock Performance

Shares of Chemed stock traded down $6.10 during trading on Friday, reaching $452.15. The company had a trading volume of 320,827 shares, compared to its average volume of 185,768. Chemed Corporation has a fifty-two week low of $408.42 and a fifty-two week high of $623.60. The company has a market cap of $6.59 billion, a price-to-earnings ratio of 23.25, a price-to-earnings-growth ratio of 2.67 and a beta of 0.46. The firm's fifty day moving average is $450.46 and its 200-day moving average is $526.54.

Chemed (NYSE:CHE - Get Free Report) last released its earnings results on Tuesday, July 29th. The company reported $4.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.02 by ($1.75). Chemed had a return on equity of 25.83% and a net margin of 11.56%.The company had revenue of $618.80 million during the quarter, compared to analysts' expectations of $650.60 million. During the same quarter in the previous year, the company earned $5.47 EPS. The firm's quarterly revenue was up 3.8% compared to the same quarter last year. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. On average, research analysts anticipate that Chemed Corporation will post 21.43 EPS for the current fiscal year.

Chemed Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 29th. Stockholders of record on Monday, August 11th were paid a $0.60 dividend. The ex-dividend date of this dividend was Monday, August 11th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.5%. This is an increase from Chemed's previous quarterly dividend of $0.50. Chemed's payout ratio is currently 12.34%.

Analyst Ratings Changes

Several brokerages have recently weighed in on CHE. Bank of America reduced their price target on Chemed from $610.00 to $595.00 and set a "buy" rating on the stock in a report on Wednesday, September 10th. Jefferies Financial Group upgraded Chemed from a "hold" rating to a "buy" rating and upped their price objective for the company from $490.00 to $550.00 in a report on Tuesday, September 2nd. Royal Bank Of Canada cut their price objective on Chemed from $640.00 to $589.00 and set an "outperform" rating on the stock in a research report on Thursday, July 31st. Oppenheimer dropped their target price on Chemed from $650.00 to $580.00 and set an "outperform" rating on the stock in a report on Thursday, July 31st. Finally, Wall Street Zen downgraded shares of Chemed from a "buy" rating to a "hold" rating in a research note on Saturday, July 5th. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Chemed has an average rating of "Buy" and a consensus price target of $578.50.

Insiders Place Their Bets

In other Chemed news, EVP Nicholas Michael Westfall sold 10,012 shares of the company's stock in a transaction that occurred on Monday, August 4th. The shares were sold at an average price of $421.91, for a total value of $4,224,162.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Patrick P. Grace sold 150 shares of the stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $463.39, for a total transaction of $69,508.50. Following the completion of the sale, the director directly owned 3,397 shares in the company, valued at approximately $1,574,135.83. This represents a 4.23% decrease in their position. The disclosure for this sale can be found here. 3.29% of the stock is currently owned by insiders.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.